This phase I trial is evaluating how safe and tolerable a new oral drug (IN10018) is, when it is given on it's own and in combination with an oral targeted therapy, for patients with uveal or NRAS-mutant melanoma that has spread to other parts of the body.
This trial is treating patients with uveal or NRAS-mutant melanoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma
Commercial Sponsor
InxMed (Shanghai) Co., Ltd.
Summary
This trial is accepting people with metastatic uveal melanoma or NRAS-mutant metastatic melanoma
Recruiting Hospitals Read More